Brain, Vol. 119, No. 2, 585-591, 1996
© 1996 Oxford University Press
research-article |
An [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease
1MRC Cyclotron Unit, Hammersmith Hospital London 2Institute of Neurology, Queen Square London 3Queens Medical Centre Nottingham, UK
Correspondence to:
Correspondence to: Dr P. K. Morrish, MRC Cyclotron Unit, Hammersmith Hospital, DuCane Road, London W12 OHS, UK
We have studied disease progression in a group of 10 patients with recent onset idiopathic Parkinson's disease [mean age 53.7±12.6 years, mean duration 18.3±6.5 months, mean unified Parkinson's disease rating scale (UPDRS) 19.0±9.5], and a group of seven patients with established Parkinson's disease (mean age 60.1±15.1 years, mean duration 70.8±35.5 months, mean UPDRS 47.9±18.1), using both clinical assessment and [18F]dopa-PET. Results were compared with those of a group of 10 normal subjects (age 66±16 years). Mean putamen [18F]dopa influx constant (K1 ) was a reliable measurement (R = 0.82) and the most sensitive marker of disease progression (r = -0.85, P < 0.0001). The mean annual rate of reduction in mean putamen Ki in the Parkinson's disease patients was 12.5% per annum, whereas the control group showed no significant change in K; over a mean of 32 months follow up. The rate of progression was more rapid in the recent onset compared with the established disease group but this did not reach statistical significance. Assuming a linear progression for the entire group we estimate symptom onset at a mean putamen K1 79% of normal with a mean preclinical period of 3.1 years.
Parkinson’s disease; PET; [18F]dopa; progression
Received August 10, 1995. Revised October 26, 1995. Accepted December 18, 1995.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Savica, J. M. Carlin, B. R. Grossardt, J. H. Bower, J. E. Ahlskog, D. M. Maraganore, A. E. Bharucha, and W. A. Rocca Medical records documentation of constipation preceding Parkinson disease: A case-control study Neurology, November 24, 2009; 73(21): 1752 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nandhagopal, L. Kuramoto, M. Schulzer, E. Mak, J. Cragg, C. S. Lee, J. McKenzie, S. McCormick, A. Samii, A. Troiano, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study Brain, November 1, 2009; 132(11): 2970 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Poewe Treatments for Parkinson disease--past achievements and current clinical needs Neurology, February 17, 2009; 72(7_Supplement_2): S65 - S73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Shu, C. G. Radu, S. M. Shelly, D. D. Vo, R. Prins, A. Ribas, M. E. Phelps, and O. N. Witte Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen Int. Immunol., February 1, 2009; 21(2): 155 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J M S Pearce The micrographia of Sir Henry Head (1861-1940) J. Neurol. Neurosurg. Psychiatry, March 1, 2008; 79(3): 307 - 307. [Full Text] [PDF]
|
|
|
|
|
|
V. Bouilleret, F. Semah, F. Chassoux, M. Mantzaridez, A. Biraben, R. Trebossen, and M. -J. Ribeiro Basal ganglia involvement in temporal lobe epilepsy: A functional and morphologic study Neurology, January 15, 2008; 70(3): 177 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mazzoni, A. Hristova, and J. W. Krakauer Why Don't We Move Faster? Parkinson's Disease, Movement Vigor, and Implicit Motivation J. Neurosci., July 4, 2007; 27(27): 7105 - 7116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Desmurget, F. Bonnetblanc, and H. Duffau Contrasting acute and slow-growing lesions: a new door to brain plasticity Brain, April 1, 2007; 130(4): 898 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lu, H. Dang, B. Middleton, Z. Zhang, L. Washburn, D. B. Stout, M. Campbell-Thompson, M. A. Atkinson, M. Phelps, S. S. Gambhir, et al. Noninvasive imaging of islet grafts using positron-emission tomography. PNAS, July 25, 2006; 103(30): 11294 - 11299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Poewe The need for neuroprotective therapies in Parkinson's disease: A clinical perspective Neurology, May 23, 2006; 66(10_suppl_4): S2 - S9. [Abstract] [Full Text]
|
|
|
|
|
|
R Hilker, A T Portman, J Voges, M J Staal, L Burghaus, T van Laar, A Koulousakis, R P Maguire, J Pruim, B M de Jong, et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation J. Neurol. Neurosurg. Psychiatry, September 1, 2005; 76(9): 1217 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Avorn, S. Schneeweiss, L. R. Sudarsky, J. Benner, Y. Kiyota, R. Levin, and R. J. Glynn Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease Arch Neurol, August 1, 2005; 62(8): 1242 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Bouilleret, F. Semah, A. Biraben, D. Taussig, F. Chassoux, A. Syrota, and M.-J. Ribeiro Involvement of the Basal Ganglia in Refractory Epilepsy: An 18F-Fluoro-L-DOPA PET Study Using 2 Methods of Analysis J. Nucl. Med., March 1, 2005; 46(3): 540 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Boska, T. B. Lewis, C. J. Destache, E. J. Benner, J. A. Nelson, M. Uberti, R. L. Mosley, and H. E. Gendelman Quantitative 1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease J. Neurosci., February 16, 2005; 25(7): 1691 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Lee, M. Schulzer, R. de la Fuente-Fernandez, E. Mak, L. Kuramoto, V. Sossi, T. J. Ruth, D. B. Calne, and A. J. Stoessl Lack of Regional Selectivity During the Progression of Parkinson Disease: Implications for Pathogenesis Arch Neurol, December 1, 2004; 61(12): 1920 - 1925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Colloby and J. O'Brien Functional Imaging in Parkinson's Disease and Dementia with Lewy Bodies J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 158 - 163. [Abstract] [PDF]
|
|
|
|
|
|
A. W. Michell, S. J. G. Lewis, T. Foltynie, and R. A. Barker Biomarkers and Parkinson's disease Brain, August 1, 2004; 127(8): 1693 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Whone, D. L. Bailey, P. Remy, N. Pavese, and D. J. Brooks A Technique for Standardized Central Analysis of 6-18F-Fluoro-L-DOPA PET Data from a Multicenter Study J. Nucl. Med., July 1, 2004; 45(7): 1135 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y F Tai and P Piccini Applications of positron emission tomography (PET) in neurology J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 669 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Marek, D. Jennings, and J. Seibyl Imaging the dopamine system to assess disease-modifying drugs: Studies comparing dopamine agonists and levodopa Neurology, September 23, 2003; 61(90063): S43 - 48. [Full Text]
|
|
|
|
|
|
K.M. Powers, T. Smith-Weller, G.M. Franklin, W.T. Longstreth Jr., P.D. Swanson, and H. Checkoway Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes Neurology, June 10, 2003; 60(11): 1761 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Winogrodzka, P Bergmans, J Booij, E A van Royen, J C Stoof, and E C Wolters [123I]{beta}-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease J. Neurol. Neurosurg. Psychiatry, March 1, 2003; 74(3): 294 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Escola, Th. Michelet, F. Macia, D. Guehl, B. Bioulac, and P. Burbaud Disruption of information processing in the supplementary motor area of the MPTP-treated monkey: A clue to the pathophysiology of akinesia? Brain, January 1, 2003; 126(1): 95 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Abbott, G. W. Ross, L. R. White, J. S. Nelson, K. H. Masaki, C. M. Tanner, J. D. Curb, P. L. Blanchette, J. S. Popper, and H. Petrovitch Midlife adiposity and the future risk of Parkinson's disease Neurology, October 8, 2002; 59(7): 1051 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Khan, D. J. Brooks, N. Pavese, M. G. Sweeney, N. W. Wood, A. J. Lees, and P. Piccini Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study Brain, October 1, 2002; 125(10): 2248 - 2256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Ribeiro, M. Vidailhet, C. Loc'h, C. Dupel, J. P. Nguyen, M. Ponchant, F. Dolle, M. Peschanski, P. Hantraye, P. Cesaro, et al. Dopaminergic Function and Dopamine Transporter Binding Assessed With Positron Emission Tomography in Parkinson Disease Arch Neurol, April 1, 2002; 59(4): 580 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Marek, R. Innis, C. van Dyck, B. Fussell, M. Early;, S. Eberly, D. Oakes, and J. Seibyl [123I]{beta}-CIT SPECT imaging assessment of the rate of Parkinson's disease progression Neurology, December 11, 2001; 57(11): 2089 - 2094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bezard, S. Dovero, C. Prunier, P. Ravenscroft, S. Chalon, D. Guilloteau, A. R. Crossman, B. Bioulac, J. M. Brotchie, and C. E. Gross Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease J. Neurosci., September 1, 2001; 21(17): 6853 - 6861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Doudet Radionuclide Imaging in Parkinson's Disease: Diagnosis, Treatment, and Disease Progression Journal of Pharmacy Practice, August 1, 2001; 14(4): 341 - 350. [Abstract] [PDF]
|
|
|
|
|
|
C. W. Olanow, R. L. Watts, and W. C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment Neurology, June 12, 2001; 56(suppl_5): S1 - S88. [Full Text] [PDF]
|
|
|
|
|
|
J. Muller, G. K. Wenning, K. Jellinger, A. McKee, W. Poewe, and I. Litvan Progression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study Neurology, September 26, 2000; 55(6): 888 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kirik, C. Rosenblad, A. Bjorklund, and R. J. Mandel Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System J. Neurosci., June 15, 2000; 20(12): 4686 - 4700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Morrish, P. Vieregge, J. Hagenah, I. Heberlein, C. Klein, and H.-P. Ludin Parkinson's disease in twins Neurology, April 25, 2000; 54(8): 1710 - 1711. [Full Text] [PDF]
|
|
|
|
|
|
A. Samii, K. Markopoulou, Z. K. Wszolek, V. Sossi, T. Dobko, E. Mak, D. B. Calne, and A. J. Stoessl PET studies of parkinsonism associated with mutation in the {alpha}-synuclein gene Neurology, December 1, 1999; 53(9): 2097 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Dujardin, A. Duhamel, E. Becquet, C. Grunberg, L. Defebvre, and A. Destee Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease J. Neurol. Neurosurg. Psychiatry, September 1, 1999; 67(3): 323 - 328. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Marek Dopaminergic Dysfunction in Parkinsonism: New Lessons from Imaging Neuroscientist, September 1, 1999; 5(5): 333 - 340. [Abstract] [PDF]
|
|
|
|
|
|
D. Berg, G. Becker, B. Zeiler, O. Tucha, E. Hofmann, M. Preier, P. Benz, W. Jost, K. Reiners, and K. W. Lange Vulnerability of the nigrostriatal system as detected by transcranial ultrasound Neurology, September 1, 1999; 53(5): 1026 - 1026. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. Shoulson Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs Science, November 6, 1998; 282(5391): 1072 - 1074. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. E. Lang and A. M. Lozano Parkinson's Disease- First of Two Parts N. Engl. J. Med., October 8, 1998; 339(15): 1044 - 1053. [Full Text] [PDF]
|
|
|
|
|
|
P K Morrish, J S Rakshi, D L Bailey, G V Sawle, and D J Brooks Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET J. Neurol. Neurosurg. Psychiatry, March 1, 1998; 64(3): 314 - 319. [Abstract] [Full Text] [PDF]
|
|